Journal Article

Recurrence of <i>Mycobacterium avium</i> Infection in Patients Receiving Highly Active Antiretroviral Therapy and Antimycobacterial Agents

Sandro K. Cinti, Daniel R. Kaul, Paul E. Sax, Laurence R. Crane and Powel H. Kazanjian

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 30, issue 3, pages 511-514
Published in print March 2000 | ISSN: 1058-4838
Published online March 2000 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/313705
Recurrence of Mycobacterium avium Infection in Patients Receiving Highly Active Antiretroviral Therapy and Antimycobacterial Agents

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

The known effects of highly active antiretroviral therapy (HAART) on opportunistic infections (OIs) range from immune restoration disease to remission of specific OIs. In the present study, Mycobacterium avium complex infection recurred in 3 patients receiving antimycobacterial therapy and HAART. At the time of the initial M. avium infection, the mean CD4 cell count was 22.3 cells/mm3, and the HIV viral load was 181,133 copies/mL. Relapse occurred a mean of 14.3 months after the first episode; the mean follow-up CD4 cell count was 89/mm3 (mean elevation of 66 cells/mm3), and the HIV viral load was <400 copies/mL in each patient. M. avium was isolated from blood (1 patient), blood and lymph node (1), and small-bowel tissue (1). M. avium infection may recur as a generalized or focal disease in those who are receiving antimycobacterial agents but whose HAART-associated CD4 cell recovery, although significant, is not optimal.

Journal Article.  2924 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.